SciSparc Ltd. Ordinary Shares (SPRC)
Stock · NASDAQ · Health Care
$1.67as of 10/16/2026
Price chart
Active signals
SPRC Signal Track Record
How signals performed across all stocks →What SPRC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 21 | -26.3% | 14% | July 29, 2026 |
| Volume Spike | 17 | -27.9% | 29% | October 7, 2026 |
| Bollinger Band Breakdown | 16 | -25.2% | 19% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -15.9% | 0% | July 25, 2025 |
| Any 20-session window (baseline) | -15.2% | 31% |
Computed by MarketWall from daily closing prices since June 14, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SPRC
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and o…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
- Website
- scisparc.com/
Fundamentals
- 1-day range
- $1.6$1.95
- Market cap
- $3.85M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-461.25
- Dividend yield
- —
- Beta
- 2.54
- Avg. volume
- 718.0K
SciSparc Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- SPRCSciSparc Ltd. Ordinary Shares$1.7▼ 15.00%Market cap $3.85MP/E —$1.63$43.65
- MBIOMustang Bio Inc. Common Stock$0.376▼ 2.59%Market cap $3.87MP/E —$0.3701$1.69
- INMInMed Pharmaceuticals Inc. Common Shares$1.32▼ 0.75%Market cap $4.01MP/E —$0.575$2.33
- RDHLRedhill Biopharma Ltd. American Depositary Shares$0.48▼ 3.81%Market cap $3.53MP/E Infinity$0.4351$2.14
- XRTXXORTX Therapeutics Inc. Common Shares$1.24▼ 12.68%Market cap $3.51MP/E —$2.42$9.85
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SPRC SciSparc Ltd. Ordinary Shares | $3.85M | — | $1.7 | ▼ 15.00% | $1.63$43.65 |
| MBIO Mustang Bio Inc. Common Stock | $3.87M | — | $0.376 | ▼ 2.59% | $0.3701$1.69 |
| INM InMed Pharmaceuticals Inc. Common Shares | $4.01M | — | $1.32 | ▼ 0.75% | $0.575$2.33 |
| RDHL Redhill Biopharma Ltd. American Depositary Shares | $3.53M | Infinity | $0.48 | ▼ 3.81% | $0.4351$2.14 |
| XRTX XORTX Therapeutics Inc. Common Shares | $3.51M | — | $1.24 | ▼ 12.68% | $2.42$9.85 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- SciSparc Agrees to Convert $2.02M Convertible Note Into Ordinary Shares At $1.50/Sharebenzinga · 10/15/2026
- SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum ArchitectureYahoo · 10/7/2026
- SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsYahoo · 9/23/2026
Insider Activity
Insider Actions →- Shrem Itschak · June 1, 2026 · Sale462 @ $10
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
SciSparc Subsidiary Reports Quantum Gene Analysis of Billions
SciSparc’s subsidiary NeuroThera Labs announced that its CliniQuantum platform successfully analyzed billions of gene combinations using real‑world clinical data on a quantum architecture owned by an S&P 500 company. The achievement shows the company’s ability to use quantum computing for big genetic analysis, a key area for drug discovery. The news comes as shares trade near $6.46, close to a support level tested 15 times, with an RSI of 40.6.
SciSparc Subsidiary Reports Quantum Gene Analysis of Billions. SciSparc’s subsidiary NeuroThera Labs announced that its CliniQuantum platform successfully analyzed billions of gene combinations using real‑world clinical data on a quantum architecture owned by an S&P 500 company. The achievement shows the company’s ability to use quantum computing for big genetic analysis, a key area for drug discovery. The news comes as shares trade near $6.46, close to a support level tested 15 times, with an RSI of 40.6.